Current View of Orphan Drug Usage in Tertiary Hospital and Rare Incurable Disease Hospital.
- Author:
Kyung Suk CHOI
1
;
Young Mi JEONG
;
Yu Jeong KIM
;
Yoon Hee KIM
;
Hyunmin GU
;
Byung Koo LEE
;
Eunsook LEE
;
Sandy Jeong RHIE
Author Information
1. College of Pharmacy and Division of Life and Pharmaceutical Sciences Graduate School, Ewha Womans University, Seoul 03760, Republic of Korea. sandy.rhie@ewha.ac.kr
- Publication Type:Original Article
- Keywords:
Orphan drug;
rare disease;
drug information
- MeSH:
Antineoplastic Agents;
Child;
Child, Orphaned*;
Counseling;
Delivery of Health Care;
Electronic Mail;
Humans;
Insurance Coverage;
Korea;
Orphan Drug Production*;
Rare Diseases;
Tertiary Care Centers*
- From:Korean Journal of Clinical Pharmacy
2016;26(2):121-127
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Until now, there is minimal number of research for overall domestic status of orphan drug use in Korea. The purpose of this study is to identify the list of orphan drugs available in Korea and to understand the status of orphan drug usage in tertiary Hospitals and rare incurable disease Hospital. METHODS: We made domestic orphan drug lists based on available orphan drugs in Korea. Based on this lists, we conducted e-mail survey from August, 2014 to September, 2014 to identify domestic status of orphan drug usage including the availability and management of orphan drugs. RESULTS: There are three hundred and eighteen orphan drugs (184 ingredients) registered in Ministry of Food and Drug Safety. Among the three hundred and eighteen orphan drugs, Two hundred and twenty-eight drugs (102 ingredients) were selected. Information on each item was collected and documented with generic and brand names, manufacturers, wholesalers, indications, FDA approval status and insurance coverage. Forty-three tertiary hospitals and thirty-two rare incurable hospitals responded to the survey questionnaire (57.3%). According to the survey result, the antineoplastics and immunomodulating agents group has the highest percentage (40%) usage in the hospital. Of fortythree tertiary hospitals, thirteen hospitals manage orphan drugs separately (30.2%). Based on the reply, most of the healthcare professionals commented the drug information related to efficacy and safety including medication counseling of orphan drugs is insufficient. CONCLUSION: Through this study we anticipate providing an understanding of orphan drug usage status in Korea. We found the limited resources to the information on orphan drugs and this information requires updating on a regular basis. This can be the basis for further studies about preparing drug information, educational resources for rare disease patients.
